greeksoup/ stock research
Stock research / United States / TVTX / Filings

Travere Therapeutics, Inc. SEC filings

Travere Therapeutics filed 21 documents with the SEC in the last twelve months, the latest report being the 10-Q of 4 August 2026. The latest filing, on 21 September 2026, was an 8-K: officer or director change.

Filings in twelve months2113 of them 8-K news
Latest report10-Qfiled 4 Aug 2026
Latest filing8-K21 Sep 2026
Last results, two-day move+14.2%results filed 4 Aug 2026
New to this? How to read this page
  1. Companies file with the SEC when something happens. 10-Q and 10-K are the quarterly and annual reports; 8-K is news that cannot wait for the next report.
  2. An 8-K says which items it covers, such as results, a change at the top or a big contract. A foreign company files a 6-K instead.
  3. The results release is usually an 8-K filed the day results come out, before the 10-Q or 10-K.
  4. Every filing links to the original on EDGAR, the SEC's own site.

Twelve months of filings

by kind

Most of the filings were other company news (8). Results came out 5 times.

Each mark is one filing on the day it was filed, in rows by kind. Hover or tap a mark for the form and what it was about.

The share price around each results release

close before to close after

Over the last 5 releases the share price moved 11.6% on average in the two days around results, the most on 30 Oct 2025 (+17.3%).

12 Jan 2026-15.8%$34.58 to $29.11
19 Feb 2026+9.0%$27.87 to $30.39
4 May 2026+1.5%$44.12 to $44.80
4 Aug 2026+14.2%$54.98 to $62.76
Daily closeResults filed

Each ring marks a results filing. The move runs from the last close before the filing to the first close after it, so it covers results released before the open or after the close. Hover the line for any day's close.

What the company told investors on 8-K

13 filings

Travere Therapeutics's 13 news filings (8-K) were mostly about results of operations (5) and officer or director change (4).

  • Results of operationsThe quarterly results release
    5 · latest 4 Aug 2026
  • Officer or director changeSomeone joined, left or changed role at the top
    4 · latest 21 Sep 2026
  • Other eventsNews the company chose to file
    3 · latest 11 May 2026
  • Material agreementA large contract or deal was signed
    2 · latest 2 Jun 2026
  • Shareholder voteResults of a vote at a shareholder meeting
    1 · latest 21 May 2026
  • New financial obligationNew debt or a borrowing
    1 · latest 11 May 2026
  • Unregistered sale of equityShares sold privately
    1 · latest 11 May 2026

Each line is one kind of news, with what it means in plain words. Each square is one filing; a filing can carry more than one kind, so the squares can add up to more than the filings. The date opens the latest one on EDGAR.

How it compares

every company on the site

    The bar ranks every company on the site from the lowest on the left to the highest on the right, in three equal thirds; the small figures under it are the values where each third starts, and the black tick is the middle company. The orange dot is this company; the grey ticks are the other companies in its industry (hover or tap for names). A hatched block is companies tied at none.

    Every filing as a table

    In the last twelve months Travere Therapeutics, Inc. filed 21 documents with the SEC of the kinds listed here: 13 current reports (8-K), about 5 results of operations; 4 officer or director change; 3 other events; 2 material agreement; 1 shareholder vote; 3 quarterly reports (10-Q), 1 employee share plan registration (S-8), 1 annual report to shareholders (ARS), 1 additional proxy material (DEFA14A), 1 proxy statement (DEF 14A), 1 annual report (10-K). The latest, filed 21 September 2026: 8-K, officer or director change. The 10-K, the 10-Qs and the proxy statement themselves, each with a link to open it, are on the documents page.

    FiledFormWhat it was aboutPeriod or event dateFiling
    21 September 20268-KOfficer or director change21 September 2026EDGAR
    4 August 202610-Qquarterly report30 June 2026EDGAR
    4 August 20268-KResults of operations4 August 2026EDGAR
    9 July 20268-KOfficer or director change6 July 2026EDGAR
    17 June 2026S-8employee share plan registrationEDGAR
    16 June 20268-KOfficer or director change12 June 2026EDGAR
    2 June 20268-KMaterial agreement1 June 2026EDGAR
    21 May 20268-KOfficer or director change, Shareholder vote19 May 2026EDGAR
    11 May 20268-KMaterial agreement, New financial obligation, Unregistered sale of equity, Other events6 May 2026EDGAR
    4 May 202610-Qquarterly report31 March 2026EDGAR
    4 May 20268-KResults of operations4 May 2026EDGAR
    14 April 20268-KOther events13 April 2026EDGAR
    6 April 2026ARSannual report to shareholders31 December 2025EDGAR
    6 April 2026DEFA14Aadditional proxy materialEDGAR
    6 April 2026DEF 14Aproxy statement19 May 2026EDGAR
    19 February 202610-Kannual report31 December 2025EDGAR
    19 February 20268-KResults of operations19 February 2026EDGAR
    13 January 20268-KOther events13 January 2026EDGAR
    12 January 20268-KResults of operations12 January 2026EDGAR
    30 October 202510-Qquarterly report30 September 2025EDGAR
    30 October 20258-KResults of operations30 October 2025EDGAR
    An 8-K is what a company files within four business days of a material event; the SEC numbers the events, and the words here are the SEC's own headings, shortened.
    Read moreForm 4, Form 144, 13F and Schedule 13D and 13G have their own pages. Prospectus supplements and correspondence are not listed.